Vonoprazan
- Generic Name
- Vonoprazan
- Brand Names
- Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16FN3O2S
- CAS Number
- 881681-00-1
- Unique Ingredient Identifier
- 1R5L3J156G
- Background
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H, K-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthe...
- Indication
Vonoprazan, in combination with amoxicillin and clarithromycin in a co-packaged product, is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. Another co-packaged product with only vonoprazan and amoxicillin is also indicated for the treatment of H. pylori infection in adults.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, Helicobacter Pylori Infection, Reflux Esophagitis (RE), Develop NSAID-induced gastric ulcers
- Associated Therapies
- -
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04729101
- Locations
- 🇺🇸
Celerion, 2420 W Baseline Rd,, Tempe, Arizona, United States
The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Showa Inan General Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04720781
- Locations
- 🇯🇵
Showa Inan General hospital, Komagane, Nagano, Japan
Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Registration Number
- NCT04558216
- Locations
- 🇺🇸
PPD Development, LP, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04545944
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 510
- Registration Number
- NCT04198363
- Locations
- 🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 1046
- Registration Number
- NCT04167670
- Locations
- 🇺🇸
Carolina Research, Greenville, North Carolina, United States
🇺🇸Synexus Clinical Research US, Inc. - Anderson, Anderson, South Carolina, United States
🇺🇸Anaheim Clinical Trials LLC, Anaheim, California, United States
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 1027
- Registration Number
- NCT04124926
- Locations
- 🇺🇸
Carolina Research, Greenville, North Carolina, United States
🇺🇸Central Sooner Research, Norman, Oklahoma, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- St. Luke's Medical Center, Philippines
- Target Recruit Count
- 82
- Registration Number
- NCT04028466
- Locations
- 🇵🇭
St. Luke's Medical Center, Quezon City, National Capital Region, Philippines
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
- Conditions
- Interventions
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Changi General Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT03908619
- Locations
- 🇸🇬
Clinical Trials & Research Unit, Singapore, Singapore
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 560
- Registration Number
- NCT03219723
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.